Abstract: The present invention concerns a topical, cosmetic or pharmaceutical preparation containing a combination of 3 or 4 solar filters comprising: one or two UVA filters to obtain a critical wavelength >370 nm, chosen from among: i. 5,6,5,6-tetraphenyl-3,3?-(1,4-phenylene)-bis[1,2,4]triazine, ii. 1,1?-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone iii. Butyl Methoxydibenzoylmethane (BMDBM), in a quantity less than 2% by weight with regard to the total weight of said composition, iv. Hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate, 2,4-Bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazine=(BEMT), one or two filters chosen from among UVB filters, except octocrylene, PABA and ethylhexyl methoxycinnamate, said composition also containing a pharmaceutically or cosmetically acceptable excipient.

Abstract: The disclosure provides microneedle patches for delivering hyaluronic acid (“HA”) to skin and methods of using the microneedle patches of the disclosure to maintain and/or improve the appearance of skin.

Abstract: The present invention provides a copolymer used as oily gelling agent with which a stable oily gelled composition can be prepared. The copolymer of the present invention is characterized by comprising a hydrophobic monomer represented by the following general formula (1) and a hydrophilic monomer represented by the following general formula (2) and/or the following general formula (3). (In formula (1), R1 is a straight-chain or branched-chain alkyl group having 16 to 22 carbon atoms. R2 is a hydrogen atom or a methyl group.) (In formula (2), R3 is a hydrogen atom, a glyceryl group, a straight-chain or branched-chain hydroxyalkyl group having 1 to 4 carbon atoms, or a polypropylene glycol group represented by —(C3H6O)nH (here, n is an integer of 2 to 10). R4 is a hydrogen atom or a methyl group.

Abstract: A crosslinked polyorganosiloxane is obtained from the free radical-initiated addition polymerization of polymerizable polyorganosiloxane containing at least two free radical polymerizable groups.

Abstract: The present invention relates to a composition comprising: (a) at least one oil; (b) at least one polyglyceryl fatty acid ester; (c) at least one silicone elastomer; and (d) at least one polysaccharide. The composition according to the present invention provides no sticky feeling or a reduced sticky feeling to the touch, and is stable, in particular stable over time and/or under elevated temperature, although the composition includes a polyglyceryl fatty acid ester.

Abstract: Pure saponins and processes for making such saponins are described herein. In addition, cosmetic compositions, such as skin care compositions, comprising such saponins and methods for improving skin health and appearance with such skincare compositions are also described herein.

Abstract: A water-insoluble composition, solid in appearance at a temperature of less than or equal to 20° C., comprising, for 100% of the mass of same:—X1% by mass of at least one lipophilic surfactant having a value HLB, H1, greater than or equal to 1 and less than 10;—X2% by mass of at least one hydrophilic surfactant having a value HLB, H2, greater than or equal to 10 and less than or equal to 20; characterised by the fact that the HLB of same=X1.H1+X2.H2, X1 and X2 varying from 2 to 60, and characterised in that it is free of acrylic polymer and/or of acetate succinate.

Abstract: A kit for mucosally administering a metastable supersaturated solution of a pharmaceutical active agent to a human patient includes a first compartment comprising a first composition comprising a pharmaceutical active agent in solution at or below equilibrium solubility, and a second composition comprising an acidic buffer. The first and second compartments maintain separation of the first and second compositions during storage, and allow for mixing of the first and second compositions to form a supersaturated solution above equilibrium solubility of the pharmaceutical active agent for immediate mucosal administration to a human patient. In one embodiment, the second composition comprises an acidic buffer and the supersaturated solution has an acidic pH. Alternatively, the second composition comprises a basic buffer and the supersaturated solution has a basic pH.

Abstract: The present invention relates to novel liquid protein formulations, particularly arginine-free liquid pharmaceutical compositions of etanercept. The invention employs particular combinations and classes of buffer systems, tonicifiers, and sugar stabilisers, optionally alongside polar ionisable amino acids (e.g. aspartic acid, glutamic acid, histidine, and lysine), to afford a viable and storable drug product.

Abstract: Solid and liquid pharmaceutical compositions comprising botulinum neurotoxin complex or high purity botulinum neurotoxin and a surfactant. The composition may comprise a crystalline agent.

Abstract: The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 ?g/hr and about 300 ?g/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.

Abstract: The present invention provides a microneedle device comprising: a substrate; a microneedle disposed on the substrate; and a coating layer formed on the microneedle; in which the coating layer comprises a recombinant follicle-stimulating hormone, arginine, and glycerin, in the coating layer, the mass of arginine is 0.07 to 0.75-fold of the mass of the recombinant follicle-stimulating hormone and the mass of glycerin is 0.1 to 2.75-fold of the mass of the recombinant follicle-stimulating hormone.

Abstract: An improved medical implant device directed to, inter alia, (i) avoiding unwanted initial drug “burst” problems, (ii) providing a more level amount of drug delivery, (iii) reducing blood clotting, (iv) reducing the amount of drug material that remains in the implant device, and/or (v) novel materials for an implant device.

Abstract: A nasal composition of improved stability, its use, and process for production. The nasal composition consists of: xylometazoline hydrochloride (1), 0.01-0.1% w/w; ipratropium bromide (2), 0.01-0.1% w/w; and pharmaceutical excipients required to form final dosage forms selected from the group consisting of: nasal drops, liquid nasal sprays, or nasal washes. The nasal composition includes the content of purified sea water as a functional, stability-improving excipient, in amounts of 5-25% w/w. The nasal composition has an osmolality within the range 270-820 mOsm/kg, the pH value within the range 3-7, preferably within the range 3-4.2 or 5.8-7.0, and most preferably within the range 3.2-4.2 where it shows improved stability.

Abstract: Provided herein is an optimized method of enhancing endogenous gonadotropins and testosterone/estrogen production and concentrations comprising administration of a therapeutically effective amount of at least one GnRH agonist to a patient in need of such treatment. A method and dosing regimen is also described for delivery across the mucosa of the oral cavity for maximizing absorption and delivery, limiting systemic exposure and unwanted side effects, effectuating a sustained increase in concentrations of sex hormones and providing a non-invasive delivery that does not require inpatient visits. The method described benefits conditions such as hypogonadism in men due to aging or disease and symptoms related to menopause in women.

Abstract: Methods and pharmaceutical compositions for treating Angelman syndrome, Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided.

Abstract: Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Abstract: Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.

Abstract: Multi-phase release compositions, methods of using the compositions, and methods for manufacturing the compositions are provided. Multi-phase release compositions include ingredients useful in sports nutrition including ingredients useful in muscle building, energy output and weight loss. Sports nutrition ingredients are designed for immediate and extended release dependent on the particular sport nutrition motivated use. One sports nutrition ingredient that can be utilized in either or both the immediate release phase or the extended release phase is phosphatidic acid.

Abstract: The present invention has an object providing microparticles having an average particle size of 100 ?m or less. The present invention provides microparticles having an average particle size of 100 ?m or less and a method for producing thereof. In addition, the present invention provides medicine, food and feedstuff comprising the microparticles having an average particle size of 100 ?m or less.

Abstract: Methods of making and resultant acidulent/carbohydrate agglomerates. The acidulent may be citric acid having particle sizes ranging from about 1 micron to 20 microns agglomerated with a soluble carbohydrate co-agglomerate to formulate the various acidulent/carbohydrate agglomerates. In certain embodiments, the carbohydrate co-agglomerate may be maltodextrin to formulate citric acid/maltodextrin agglomerates. These citric acid/maltodextrin agglomerates are shelf stable when dry, have improved flowability, compressibility, mixability; dissolve easily and quickly in water; and provide an easy ready-to-use formulation that is suitable for use in compounding various food and pharmaceutical products.

Abstract: Tamper resistant controlled release formulations.

Abstract: A solid oral pharmaceutical composition of promethazine, hydrocodone and acetaminophen, or a pharmaceutically acceptable salt thereof is provided. The composition comprises promethazine formulated for immediate release, both hydrocodone and acetaminophen formulated for controlled release, and at least one of the hydrocodone and acetaminophen formulated for immediate release.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: Provided are a film coating composition containing a PVA having a degree of hydrolysis of 85.0 to 89.0 mol %, characterized in that even when the composition is used for coating of tablets without any additives other than PVAs, the tablets do not tend to stick to each other; a solid oral formulation using the composition; and a method for producing the same.

Abstract: The present invention discloses a novel film coating composition of polyvinyl alcohol (PVA) in combination with sugar, and a plasticizer or a combination of plasticizers resulting in a composition which is non tacky and easily dispersible in water at high solids content. The coating compositions help in achieving higher spray rates, disperse in less solvent i.e water, and helps in reduction of coating process time. Further the resultant film which when coated onto substrates exhibits good adhesion and provides smooth surface to substrates.

Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a mRNA solution and a lipid solution, wherein the mRNA solution and/or the lipid solution are at a pre-determined temperature greater than ambient temperature.

Abstract: The invention relates to a process for the preparation of a product comprising one or more nanoparticles of calcium phosphate (CaP-NP) with negative surface charge having a ?-potential in the range from ?41.0 mV to ?27.0 mV comprising the steps of: a) maintaining a mixture having a pH in the range from 7 to 10 and comprising an aqueous solution of calcium, an aqueous solution of phosphate and a solution of citrate ions at a temperature in the range from 20° C. to 40° C. for a time in the range from 30 seconds to 10 minutes; b) removing non-reacted ions from the solution of step a), thus obtaining a suspension of one or more nanoparticles of calcium phosphate (CaP-NP); c) recovering the product of one or more nanoparticles of calcium phosphate (CaP-NP) from the suspension of step b). In an advantageous embodiment, the process of the invention provides, in the mixture of step a), also an aqueous solution of one or more therapeutic/diagnostic compounds.

Abstract: To provide a packaging body for a patch exhibiting excellent temporal stability of a drug, a patch product equipped with the patch and a packaging bag, and a method of manufacturing the patch product. A patch product equipped with a packaging bag formed of a laminate composed of at least three or more layers including a cyclic polyolefin film and a lidocaine- or rivastigmine-containing patch housed in the packaging bag, a method of the patch product, and a packaging body for a patch formed of a laminate including a cyclic polyolefin film.

Abstract: The present invention provides a gel patch comprising an adhesive mass layer on a backing fabric, wherein the adhesive mass layer contains glycol salicylate, a water-soluble polymer, water and glycerin, and the content of glycerin is 8 to 15 times the content of glycol salicylate on the basis of mass.

Abstract: The present invention provides a gel patch comprising a base fabric, an adhesive layer, and a release liner in this order, wherein the adhesive layer contains a physiologically active substance, a water-soluble (meth)acrylic polymer, water, a surfactant, and poly(methyl acrylate/2-ethylhexyl acrylate), and the surfactant comprises a polyethylene glycol fatty acid ester or a polyoxyethylene sorbitan fatty acid ester.

Abstract: The present invention relates to calcifediol soft capsules, to their use in the treatment or prevention of diseases related to vitamin D deficiency, such as vitamin D deficiency, demineralization such as hypocalcemia and hypophosphatemia, renal osteodystrophy, rickets, osteoporosis, osteopenia, osteoarthritis, osteoarthrosis, osteomalacia, hypoparathyroidism, and inflammatory bowel disease, and to their process of manufacture.

Abstract: Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.

Abstract: Pharmaceutical compositions having enhanced active component permeation properties are described.

Abstract: Disclosed herein are ketamine derivatives that have been modified to reduce or prevent transference across the blood brain barrier. The ketamine derivatives will allow the reduction of pain in the patients without complications associated with psychotropic effects typically associated with unmodified ketamine.

Abstract: The present invention provides a sulphur-containing compound for use in the prophylaxis or treatment of an infection associated with at least one microbe or microbial strain displaying at least some degree of drug resistance. Also provided is a product comprising a first agent being a sulphur-containing compound and a second agent being an antimicrobial agent, in particular an antibiotic agent.

Abstract: The present invention provides microparticles comprising a sulphur-containing compound, such as cysteamine, or a pharmaceutically acceptable salt, hydrate or ester thereof. Also provided is a composition comprising the microparticles and a stabilizing agent.

Abstract: Methods of treating Prader-Willi syndrome in a subject in need of treatment are provided. The methods include administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R, R?, X, Y and Z are defined as set forth in the specification. In embodiments, an effective amount of captodiamine or a pharmaceutically acceptable salt thereof is administered to the subject.

Abstract: Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: This invention discloses 3-aminobenzamide derivatives as ?-lactam antibiotic adjuvants of chemical formula (I), processes for preparing them and their use. The derivatives can act as ?-lactam antibiotic adjuvants for the treatment of methicillin-resistant staphylococcal infections.

Abstract: The present invention relates to method of treatment of hepatitis C using bufexamac or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering bufexamac or a derivative thereof in combination with one or more anti-hepatitis C drugs.

Abstract: A nasal irrigation solution (or composition) for pre- and post-operation sinus surgery and for use as a daily nasal cleanser. The composition, which may be in a powder form, may include lactated ringers with xylitol. This composition may be mixed with sterile water prior to nasal irrigation.

Abstract: The present invention relates to a medical dermatological preparation for external use comprising an active drug, polyoxyethylene arachyl ether, stearyl alcohol, a liquid oily ingredient, a moisturizing ingredient and water, and provides a medical dermatological preparation for external use, which reduces occurrence or degree of a side effect such as skin irritation in the medical dermatological preparation for external use. The present invention provides particularly a medical dermatological preparation for external use, which comprises adapalene and reduces occurrence and degree of a side effect such as skin irritation.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.

Abstract: Compositions and methods for treating various cardiovascular disorders include targeted delivery of glutamate for impairing a targeted portion of the autonomic nervous system (ANS). Targeted delivery may be via direct injection into the targeted portion of the ANS or via vascular injection of magnetically-targetable nanoparticles.

Abstract: A solution for lysis of particles and fibers that adhere to a lens capsule of the eye during cataract operations contains 0.5-3.5 wt.-% lysine, particularly L-lysine, in an isotonic to hypertonic aqueous solution.

Abstract: In various embodiments a cancer treatment method is provided based on inhibition of proline catabolism. When combined with p53 restoration therapy and/or inhibition of glutaminase, the inhibition of proline catabolism results in a “synthetic lethal” and synergistic anticancer response. Novel suicide inhibitors that induce the degradation of proline dehydrogenase (PRODH) are also provided. Also provided is a method of assaying PRODH to identify responders/non-responders to inhibition of proline catabolism and/or glutaminase.